Natco Pharma Ltd‘s Canadian subsidiary has acquired 40 million shares in eGenesis Inc., a leading biotechnology company specializing in xenotransplantation, for USD 8 million. Xenotransplantation involves developing human-compatible organs for transplants, and eGenesis is at the forefront of this technology. Their Genome Engineering and Production platform addresses cross-species molecular incompatibilities and viral risks through genetic engineering, offering significant advancements in organ transplantation.
eGenesis is currently focusing on developing transplant solutions for kidney, acute liver failure, and heart conditions. Rajeev Nannapaneni, Vice Chairman and CEO of Natco Pharma, expressed enthusiasm about the partnership, highlighting the potential of xenotransplantation to address the global shortage of transplantable organs and reduce waitlist mortality.
Mike Curtis, CEO of eGenesis Inc., welcomed Natco’s investment, noting that the funds will be instrumental in advancing their research and bringing innovative therapies to market. Notably, in March 2024, eGenesis achieved a significant milestone by performing the world’s first porcine kidney transplant in a living patient, authorized by the U.S. FDA under the Expanded Access pathway.